Repligen vs TG Therapeutics
Repligen reported revenue of $738 million in fiscal 2025, 1.2 times TG Therapeutics' $616 million in fiscal 2025. Repligen's revenue grew 16.4% in its latest year, and TG Therapeutics' grew 87.3%. Repligen had an operating margin of 7.5%, against 20.0% at TG Therapeutics. Free cash flow was $94 million at Repligen and −$25 million at TG Therapeutics.
Side by side
| Repligen | TG Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $738M | $616M |
| Revenue growth | 16.4% | 87.3% |
| Revenue growth a year, last 5 years | 15.0% | 398.6% |
| Gross margin | 52.3% | 83.7% |
| Operating margin | 7.5% | 20.0% |
| Net margin | 6.6% | 72.6% |
| Free cash flow | $94M | −$25M |
| Free cash flow margin | 12.7% | −4.0% |
| Return on capital | 2.4% | 29.0% |
| Net debt to EBITDA | −1.7x | 0.4x |
| Dividends and buybacks | $0M | $91M |
| Change in diluted share count | — | 0.7% |
| Last close | $173.49 | $59.83 |
| P/E at the last close | — | 21.8× |
| Insider trades, last 12 months | sold $14.2 million | sold $437,650 |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
RepligenTG Therapeutics
Operating margin
Percent of revenue
RepligenTG Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
RepligenTG Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Repligen and TG Therapeutics pages.